Trastuzumab emtansine: Indication of major added benefit in one subpopulation

April 7, 2014, Institute for Quality and Efficiency in Health Care

The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, i.e. that overexpresses the human epidermal growth factor receptor 2. Patients must have already received trastuzumab or a taxane – alone or in combination. They should also have already received treatment for the locally advanced or metastatic disease or have developed disease recurrence during or within six months of completing adjuvant therapy.

The Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the added benefit of the conjugate in these . It distinguished between four subpopulations and appropriate comparator therapies. IQWiG found an indication of a major added benefit for patients who have received previous treatment with trastuzumab and taxanes and with anthracyclines. For the remaining three subpopulations, an added benefit is not proven.

Antibody combined with mitotic inhibitor

If the cancer cells in locally advanced breast cancer or breast cancer that has already formed metastases produce excessive quantities of the growth factor receptor HER2, the disease progresses particularly aggressively because the cells multiply rapidly and hardly respond to conventional chemotherapy. In this HER2-positive breast cancer, the patient can be treated with the antibody drug trastuzumab, which blocks the receptor.

However, this is often not sufficient to stop the carcinoma from spreading. The drug manufacturer now combined trastuzumab with a strong cell division inhibitor: Whereas the antibody aims to block the receptor from outside the cell, the inhibitor is designed to destroy the tumour cells from within. IQWiG was commissioned to find out in an early benefit assessment whether, and if so, which patients benefit from this new treatment.

Different comparator therapy depending on stage and pretreatment

Depending on the stage of the breast cancer and the previous treatments received, the G-BA distinguished between four subpopulations, each with its own appropriate comparator therapy. In locally advanced, unresectable breast cancer without metastases, the new conjugate was to be compared with radiotherapy. In metastatic breast cancer that has already been treated with anthracyclines, taxanes and trastuzumab, chemotherapy with lapatinib and capecitabine was the appropriate comparator therapy.

In metastatic breast cancer that has already been treated with taxanes and trastuzumab, but not with anthracyclines, the G-BA specified an anthracycline as comparator therapy – unless this treatment was not an option for the patients. Then the conjugate was to be compared with a treatment tailored to the individual patient under consideration of the approval of the drugs used.

Added benefit could only be derived for one subpopulation

The manufacturer presented no relevant data for three of the four subpopulations: In locally advanced unresectable breast cancer, it envisaged lapatinib and capecitabine as comparator therapy instead of radiotherapy. It also considered this combination to be suitable for patients who have not yet received anthracyclines. However, this contradicts the approval of lapatinib, according to which treatment with lapatinib and capecitabine always has to be preceded by a treatment including anthracyclines. These deviations from the appropriate comparator therapies were not sufficiently justified so that an added benefit of trastuzumab emtansine in these cases is not proven.

For patients with who have already received anthracyclines, the manufacturer cited results from the EMILIA study. Patients who have been pretreated with anthracyclines and now received either the conjugate or lapatinib and capecitabine also participated in this open-label, randomized controlled trial.

Positive effects predominate

This study showed both positive and negative effects of trastuzumab emtansine. The positive effects regarding the outcome categories "mortality", "health-related quality of life" and "serious or severe side effects" together provide an indication of a major added benefit. One out of two women who received trastuzumab emtansine was still alive after 31 months – compared with 24 months under lapatinib and capecitabine. Severe hand-foot syndrome, which can be caused by chemotherapy, was also considerably less common than in the comparator group.

This was offset by a hint of greater harm in non-serious and non-severe side effects. This harm was far from outweighing the benefit because these were mainly mild cases of nose bleed.

Overall, there was an indication of a major added benefit of trastuzumab emtansine – but only for patients with metastatic HER2-positive who have already been treated with anthracyclines, taxanes and trastuzumab.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

Explore further: Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

More information: An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website ", published by IQWiG, provides easily understandable and brief German-language information on trastuzumab emtansine.

The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of trastuzumab emtansine. More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on

Related Stories

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

April 7, 2014
The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults ...

Ipilimumab in advanced melanoma: Added benefit for non-pretreated patients not proven

March 18, 2014
The German Institute for Quality and Efficiency in Health Care (IQWiG) already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received ...

Enzalutamide: IQWiG assessed data subsequently submitted by the manufacturer

February 21, 2014
Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic ...

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients

April 3, 2014
Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, ...

Added benefit of eribulin in breast cancer is not proven

August 16, 2012
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

Afatinib: Added benefit depends on mutation status

February 19, 2014
Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations ...

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.